Table II.
Main characteristics of patients with acquired immunodeficiencies and SARS-CoV-2 infection
| Acquired immunodeficiency (no. of patients) | Principal diagnosis (no. of patients) | Outcome (no. of patients) | Note | Reference |
|---|---|---|---|---|
| Prednisolone and mycophenolate mofetil (1) Steroid (1) Chemotherapy (1) |
SLE (1) Nephrotic syndrome (1) Extrarenal rhabdoid tumor (1) |
All recovered without any sequelae | The clinical course after SARS-CoV-2 infection was not different compared with the general population | 123 |
| MTX (1) Canakinumab (3) |
AID (3) FMF (1) |
All recovered without any sequelae | The clinical course after SARS-CoV2 infection was not different compared with the general population | 124 |
| Sirolimus (2) Tacrolimus (1) |
Renal trasplant (3) | Mild course | The clinical course after SARS-CoV-2 infection was not different compared with the general population | 125 |
| Ruxolitinib (1) Methotrexate (1) Prednisone and tacrolimus (2) |
HSCT (1) T-ALL (1) Trasplant kidney/liver (2) |
Secondary HLH (1) | The clinical course after SARS-CoV-2 infection was not different compared with the general population | 126 |
| Chemotherapy (2) | Ewing sarcoma (1) Wilms tumor (1) |
Mild course | Pediatric cancer patients have milder disease compared with adults with malignancies | 127 |
| Cyclosporine and prednisone (2) Prednisone and tacrolimus (1) Tacrolimus and azathioprine (1) |
Heart transplant (4) | Mild course | Young patients have a mild SARS-CoV-2 clinical course | 128 |
| Immunosuppressive chemotherapy (98) | Cancer (leukemia, lymphoma, CSN tumor, solid tumor) (98) | Severe course (17) Mechanical ventilation (7) Death (4) |
Pediatric cancer patients have a higher risk of severe course after SARS-CoV-2 infection compared with the general population, but the risk is lower compared with the adult counterparts | 129 |
| Methotrexate (17) Hydroxychloroquine (8) Oral glucocorticoids (8) TNF inhibitor (38) Other (15) |
Psoriatic arthritis (21) Rheumatoid arthritis (20) Ulcerative colitis (17) Crohn disease (20) Other (9) |
Required hospitalization (14) Admission to intensive care (1) Invasive mechanical ventilation (1) Death (1) |
The clinical course after SARS-CoV-2 infection was not different compared with the general population | 112 |
| Prednisone (12) Immunosoppressive agent (7) |
SLE (17) | Required hospitalization (14) Admission to intensive care (7) Invasive mechanical ventilation (5) Death (4) |
130 | |
| Prednisolone (189) DMARDs (492) |
Rheumatoid arthritis (230) Systemic lupus erythematosus (85) Psoriatic arthritis (74) Axial spondyloarthritis or other spondyloarthritis (48) Vasculitis (44) Sjögren syndrome (28) Other inflammatory arthritis (21) Inflammatory myopathy (20) Gout (19) Systemic sclerosis (16) Polymyalgia rheumatica (12) Other (38) |
Required hospitalization (277) Death (55) |
The clinical course after SARS-CoV-2 infection was not different compared with the general population | 114 |
| HIV (5) | All 5 patients were symptomatic and required hospitalization. Oxygen therapy (2) |
131 | ||
| HIV (5) | Required hospitalization (5) Admission to intensive care (2) Invasive mechanical ventilation (1) |
132 | ||
| HIV (33) | Critical course (8) Required hospitalization (8) Admission to intensive care (6) Invasive mechanical ventilation (4) Death (3) |
The clinical course after SARS-CoV-2 infection was not different compared with the general population | 133 | |
| HIV (38) | Severe course (13) Admission to intensive care (6) Invasive mechanical ventilation (5) Death (2) |
The clinical course after SARS-CoV2 infection was not different compared with the general population | 134 | |
| HIV (88) | Severe course (18) Death (18) |
The clinical course after SARS-CoV2 infection was not different compared with the general population | 135 | |
| HIV (31) | Severe/critical course (28) Mechanical ventilation (8) Death (8) |
The clinical course after SARS-CoV-2 infection was not different compared with the general population | 136 |
AID, Autoinflammatory diseases; CNS, central nervous system; DMARD, disease-modifying antirheumatic drug; HLH, hemophagocytic lymphohistiocytosis; HSCT, hematopoietic stem cell transplantation; FMF, familial Mediterranean fever; MTX, metothrexate; SLE, systemic lupus erythematous; T-ALL, T-cell acute lymphoblastic leukemia.